![Tai-An Lin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Tai-An Lin formerly worked at EMD Serono, Inc., as Director-Immuno Oncology Translational from 2016 to 2019, Springworks Therapeutics, Inc., as Chief Scientific Officer from 2023 to 2025, and Black Diamond Therapeutics, Inc., as SVP-Translational Science & Discovery Biology.
Dr. Lin received his doctorate degree from the University of Missouri.
Former positions of Tai-An Lin
| Companies | Position | End |
|---|---|---|
| SPRINGWORKS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/07/2025 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Corporate Officer/Principal | 01/09/2019 |
| BLACK DIAMOND THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Tai-An Lin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
7
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
University of Missouri
 University of Missouri Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
Black Diamond Therapeutics, Inc.
 Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Springworks Therapeutics, Inc.
 Springworks Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes medicines for nervous system disorders | Health Technology |
- Stock Market
- Insiders
- Tai-An Lin
